Mevrometostat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Mevrometostat
- Molecular weight
- 467.35
- Structure (SMILES)
- COc1cc(C)[nH]c(=O)c1CN1CCc2c(Cl)cc([C@H](OC)C3COC3)c(Cl)c2C1=O
- Mervometostat (PF-06821497)
- mervometostat pf 06821497
- mevrometostat
- Mevrometostat
- mevrometostat [INN]
- MEVROMETOSTAT [USAN]
- Mevrometostat [WHO-DD]
- mevrometostat inn
- mevrometostat usan
- mevrometostat who dd
- Oral PF-06821497
- pf 06821497
- Pf-06821497
- PF-06821497
- CAS registry numbers
- 1844849-10-0
- ChEMBL ID
- CHEMBL4080228
- InChIKey
- RXCVUHMIWHRLDF-HXUWFJFHSA-N
- PubChem compound IDs
- 118572065
- FDA ingredient codes (UNII)
- S4L4MM20B6
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- mevrometostat
- Type
- Synthetic organic
- Drug name stem
- -stat
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- enhancer of zeste 2 polycomb repressive complex 2 subunit
- Gene symbol
- EZH2
- Protein identifier
- Q15910
- Median affinity
- 10
- Affinity units
- pKi
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018906
- Highest recorded phase
- 1
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 80.86
- Calculated partition coefficient (ALogP)
- 3.53
- Calculated partition coefficient (XLogP)
- 2.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 31
- Molecular formula
- C22H24Cl2N2O5
- Monoisotopic mass
- 466.1062273
- Natural product
- No
- Recorded assays
- 195
- Active assays
- 10
Active assay types
- Confirmatory
Distribution coefficient (LogD)
- Median
- 1.9
- Mean
- 1.9
- Minimum
- 1.9
- Maximum
- 1.9
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Solubility
- Median
- 315
- Mean
- 315
- Minimum
- 315
- Maximum
- 315
- Unit
- ug/mL
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Related records
Trials (7)
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
- A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.
- A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
In development for (5)
- Diffuse large B-cell lymphoma Phase 1
- Follicular lymphoma Phase 1
- Neoplasm Phase 1
- Prostate cancer Phase 1
- Small cell lung carcinoma Phase 1